Nuvectis Pharma (NVCT) Expected to Announce Quarterly Earnings on Tuesday

Nuvectis Pharma (NASDAQ:NVCT) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.

Nuvectis Pharma (NASDAQ:NVCT) last released its earnings results on Tuesday, May 6th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.03. On average, analysts expect Nuvectis Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nuvectis Pharma Trading Down 2.3%

Nuvectis Pharma stock opened at $7.60 on Tuesday. Nuvectis Pharma has a 1 year low of $4.44 and a 1 year high of $11.80. The company has a market cap of $158.76 million, a PE ratio of -6.73 and a beta of -0.25. The company’s 50-day moving average is $8.43 and its two-hundred day moving average is $8.20.

Insider Buying and Selling at Nuvectis Pharma

In other news, major shareholder Marlio Charles Mosseri purchased 5,603 shares of the business’s stock in a transaction that occurred on Friday, June 20th. The shares were acquired at an average cost of $7.99 per share, for a total transaction of $44,767.97. Following the transaction, the insider directly owned 2,981,806 shares of the company’s stock, valued at approximately $23,824,629.94. The trade was a 0.19% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. In the last 90 days, insiders have purchased 75,306 shares of company stock valued at $615,781. Company insiders own 30.52% of the company’s stock.

Institutional Trading of Nuvectis Pharma

An institutional investor recently bought a new position in Nuvectis Pharma stock. Jane Street Group LLC bought a new position in shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 42,299 shares of the company’s stock, valued at approximately $413,000. Jane Street Group LLC owned approximately 0.20% of Nuvectis Pharma as of its most recent filing with the Securities and Exchange Commission. 96.77% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

NVCT has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $15.00 target price (up from $11.00) on shares of Nuvectis Pharma in a research report on Wednesday, April 30th. Maxim Group assumed coverage on shares of Nuvectis Pharma in a research report on Wednesday, April 2nd. They issued a “buy” rating and a $17.00 price target on the stock. Finally, Wall Street Zen downgraded shares of Nuvectis Pharma from a “hold” rating to a “sell” rating in a research report on Sunday, June 29th.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.